The hypothalamus receives neuronal afferents from numerous sources including inputs from limbic structures, such as the amygdala and hippocampus, and from brainstem regions involved in the regulation of the cardiovascular system and other autonomic functions. These afferents using a vast array of neurotransmitters and neuropeptides influence the activity of the hypothalamic neurons which synthesize and secrete the hypothalamic releasing and release-inhibiting factors into the hypophyseal portal circulatory system. The afferents can modulate the activity of the hypothalamic neurons by forming synapses on the neuronal cell body, on the nerve terminals in the median eminence or both. The chemicals most frequently used as neurotransmitters are the biogenic amines, including the catecholamines (norepinephrine, dopamine and epinephrine), serotonin, acetylcholine and gamma-aminobutyric acid (GABA). The stimulatory influence of norepinephrine, serotonin, and acetylcholine on the secretion of corticotropin (ACTH) in rodents and man will be discussed, whereas GABA exerts an inhibitory effect on the secretion of ACTH in both man and rodents. These effects appear to be mediated by changes in the secretion of the corticotropin-releasing hormone (CRH) and vasopressin into the hypophyseal portal circulation. Numerous neuropeptides appear to alter the secretion of ACTH in the rat. We will discuss the stimulatory actions of neuropeptide Y (NPY), angiotensin II, and peptides of immune cell origin on the secretion of ACTH and CRH. The opioid peptides inhibit the secretion of CRH into the portal blood, however, they exert a potent stimulatory effect on prolactin secretion in the rat and man. We will discuss the receptor subtypes involved in mediating these effects and the interactions of the opioid peptides with the neurotransmitter-containing neurons which project to the hypothalamus. This discussion will focus on the factors which impinge on the releasing factor-containing neurons in the hypothalamus and how they can be studied under in vivo and in vitro conditions.
1. Allen YS, Adrian TE, Allen JM, Tatemoto K, Crow TJ, Bloom SR, and Polak JM (1983). Neuropeptide Y distribution in the rat brain.Science221: 877–879.
2.
2. Antin J, Gibbs J, Holt J, Young RC, and Smith GP (1975). Cholecystokinin elicits the complete behavioral sequence of satiety in rats.J. Comp. Physiol. Psychol.89: 784–790.
3.
3. Assenmacher I, Szafarczyk A, Alonso G, Ixart G, and Barbanel G (1987). Physiology of neural pathways affecting CRH secretion.Ann. NY Acad. Sci.512: 149–161.
4.
4. Bai FL, Yamano M, Shiotani Y, Emson PC, Smith AD, Powell JF, and Tohyama M (1985). An arcuatoparaventricular and dorsomedial hypothalamic neuropeptide Y-containing system which lacks noradrenaline in the rat.Brain Res.331: 172–175.
5.
5. Berelowitz M, Firestone SL, and Frohman LA (1981). Effects of growth hormone excess and deficiency on hypothalamic somatostatin content and release and on tissue somatostatin distribution.Endocrinology109: 714–719.
6.
6. Berkenbosch F, van Oers J, del Rey A, Tilders F, and Besedovsky H (1987). Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1.Science238: 524–526.
7.
7. Besedovsky HO, del Rey A, and Sorkin E (1981). Lymphokine-containing supernatants from Con-A stimulated cells increase corticosterone blood levels.J. Immunol.126: 385–387.
8.
8. Besedovsky HO, del Rey A, Sorkin E, and Dinarello CA (1986). Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones.Science233: 652–654.
9.
9. Breder CD, Dinarello CA, and Saper CB (1988). Interleukin-1 immunoreactive innervation of the human hypothalamus.Science240: 321–324.
10.
10. Brody MJ and Johnson AK (1980). Role of the anteroventral third ventricle region in fluid and electrolyte balance, arterial pressure regulation, and hypertension. In: Frontiers in Neuroendocrinology, L Martini and WF Ganong (eds). Raven Press, New York, 6: 249–292.
11.
11. Calogero AE, Gallucci WT, Bernardini R, Sauotis C, Gold PW, and Chrousos GP (1988). Effect of cholinergic agonists and antagonists on rat hypothalamic corticotropin-releasing hormone secretionin vitro. Neuroendocrinology47: 303–308.
12.
12. Chavkin C, James IF, and Goldstein A (1982). Dynorphin is a specific endogenous ligand of the kappa opioid receptor.Science215: 413–415.
13.
13. Cintra A, Fuxe K, Harfstrand A, Agnati LF, Wikstrom AC, Vale W, and Gustafsson JA (1987). Evidence for the presence of glucocorticoid receptor immunoreactivity in corticotrophin releasing factor and in growth hormone releasing factor immunoreactive neurons of the rat di- and telencephalon.Neurosci. Lett.76: 269–274.
14.
14. Colonna VG, Cattaneo E, Cocchi D, Muller EE, and Maggi A (1988). Growth hormone regulation of growth hormone-releasing hormone gene expression.Peptides9: 985–988.
15.
15. Demarest KT and Moore KE (1981). Disruption of 5-hydroxy-tryptaminergic neuronal function blocks the action of morphine on tuberoinfundibular neurons.Life Sci.28: 1345–1351.
16.
16. Finley JCW, Lindstrom P, and Petrusz P (1981). Immunocytochemical localization of beta-endorphin containing neurons in the rat brain.Neuroendocrinology33: 28–42.
17.
17. Fuxe K, Ganten D, Hokfelt T, and Bolme P (1976). Immunohistochemical evidence for the existence of angiotensin II-containing nerve terminals in the brain and spinal cord of the rat.Neurosci. Lett.2: 229–234.
18.
18. Ganong WF and Murakami K (1987). The role of angiotensin II in the regulation of ACTH secretion.Ann. NY Acad. Sci.512: 176–186.
19.
19. Gibbs DM and Vale W (1982). Presence of corticotropin releasing factor-like immunoreactivity in hypophysial portal blood.Endocrinology111: 1418–1420.
20.
20. Gibbs DM and Vale W (1982). Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin releasing factor and vasopressin secretion into hypophysial portal blood.Brain Res.280: 176–179.
21.
21. Gillies G and Lowry PJ (1982). Corticotropin-releasing hormone and its vasopressin component. In: Frontiers in Neuroendocrinology, WF Ganong and L. Martini (eds). Raven Press, New York, 7: 45–75.
22.
22. Goldstein A (1979). Endorphins and pain: A critical review. In: Mechanisms of Pain and Analgesic Compounds, RF Beers Jr and EG Bassett (eds). Raven Press, New York, pp. 249–262.
23.
23. Grossman A and Rees L (1983). The neuroendocrinology of opioid peptides.Brit. Med. Bull.39: 83–88.
24.
24. Gudelsky GA and Porter JC (1979). Morphine- and opioid peptide-induced inhibition of the release of dopamine from tuberoinfundibular neurons.Life Sci.25: 1697–1702.
25.
25. Gudelsky GA and Porter JC (1980). Release of dopamine from tuberoinfundibular neurons into pituitary stalk blood after prolactin or haloperidol administration.Endocrinology106: 526–529.
26.
26. Gudelsky GA, Berry SA, and Meltzer HY (1989). Neurotensin activates tuberoinfundibular dopamine neurons and increases serum corticosterone in the rat. Neuroendocrinology (in press).
27.
27. Guillaume V, Conte-Devolx B, Szafarczyk A, Malaval F, Pares-Herbute N, Grino M, Alonso G, Assenmacher I, and Oliver C (1987). The corticotropin-releasing factor release in rat hypophysial portal blood is mediated by brain catecholamines.Neuroendocrinology46: 143–146.
28.
28. Gustafson EL and Moore RY (1987). Noradrenaline and neuropeptide Y innervation of the rat hypothalamus are differently affected by 6-hydroxydopamine.Neurosci. Lett.83: 53–58.
29.
29. Haas DA and George SR (1987). Neuropeptide Y administration acutely increases hypothalamic corticotropin-releasing factor immunoreactivity: Lack of effect in other rat brain regions.Life Sci.41: 2725–2731.
30.
30. Harfstrand A, Eneroth P, Agnati LF, and Fuxe K (1987). Further studies on the effects of central administration of neuropeptide Y on neuroendocrine function in the male rat: Relationship to hypothalamic catecholamines.Reg. Peptides17: 167–179.
31.
31. Haskins JT, Gudelsky GA, Moss RL, and Porter JC (1981). Ionophoresis of morphine into the arcuate nucleus: Effects on dopamine concentrations in hypophysial portal plasma and serum prolactin concentrations.Endocrinology108: 767–771.
32.
32. Hokfelt T, Holets VR, Staines W, Meister B, Melander T, Schalling M, Schultzberg M, Freedman J, Bjorklund A, Olson L, Lindh B, Elfvin L-G, Lundberg JM, Lindgren JA, Samuelsson B, Pernow B, Terenius L, Post C, Everitt B, and Goldstein M (1986). Coexistence of neuronal messengers–An overview. In: Progress in Brain Research, T Hokfelt, K Fuxe, and B Pernow, (eds). Elsevier, Amsterdam, 68: 33–70.
33.
33. Hoyer D, Engle G, and Kalkman HO (1985). Molecular pharmacology of 5-HT1 and 5-HT2 recognition sites in rat and pig brain membranes: Radioligand binding studies with [3H]-5-HT, [3H]-8-OH-DPAT, (-)[125I] iodocyanopindolol, [3H] mesulergine and [3H] ketanserin.Eur. J. Pharmacol.118: 13–23.
34.
34. Inoue T, Kato Y, Koshiyama H, Yanaihara N, and Imura H (1988). Galanin stimulates the release of vasoactive intestinal polypeptide from perifused hypothalamic fragments in vitro and from periventricular structures into the cerebrospinal fluid in vivo in the rat.Neurosci. Lett.85: 95–100.
35.
35. Jones MT, Gillham B, Campbell EA, Al-Taher ARH, Chuang TT, and DiSciullo A (1987). Pharmacology of neural pathways affecting CRH secretion.Ann. NY Acad. Sci.512: 162–175.
36.
36. Keller-Wood ME and Dallman MF (1984). Corticoid inhibition of ACTH secretion.Endocrine Rev.5: 1–24.
37.
37. Kiss JZ, Mezey E, and Skirboll L (1984). Corticotropin-releasing factor-immunoreactive neurons of the paraventricular nucleus become vasopressin positive after adrenalectomy.Proc. Natl. Acad. Sci. USA81: 1854–1858.
38.
38. Koenig JI, Mayfield MA, Coppings RJ, McCann SM, and Krulich L (1980). Role of central nervous system neurotransmitters in mediating the effects of morphine on growth hormone and prolactin secretion in the rat.Brain Res.197: 453–468.
39.
39. Koenig JI and Krulich L (1984). Differential role of multiple opioid receptors in the regulation of secretion of prolactin and growth hormone in rats. In: Opioid Modulation of Endocrine Function, G Delitala, M Motta, and M Serio, (eds). Raven Press, New York, pp. 89–98.
40.
40. Koenig JI, Meltzer HY, Devane GD, and Gudelsky GA (1986). The concentration of arginine vasopressin in pituitary stalk plasma of the rat following adrenalectomy or morphine.Endocrinology118: 2534–2539.
41.
41. Koenig JI, Meltzer HY, and Gudelsky GA (1986). Morphine or capsaicin alters the secretion of beta-endorphin into the hypophysial portal vasculature of the rat.Neuroendocrinology43: 611–617.
42.
42. Koenig JI, Gudelsky GA, and Meltzer HY (1987). Evidence for a role of 5-HT1a and 5-HT2 receptors in the stimulation of corticosterone and beta-endorphin secretion in the rat.Eur. J. Pharmacol.137: 1–8.
43.
43. Koenig JI (1987). Adrenalectomy-induced changes in hypophysial portal blood concentration of corticotropin-releasing factor in the rat.Soc. Neurosci.10417: .
44.
44. Koshiyama H, Kato Y, Inoue T, Murakami Y, Ishikawa Y, Yanaihara N, and Imura H (1987). Central galanin stimulates pituitary prolactin secretion in rats: Possible involvement of hypothalamic vasoactive intestinal polypeptide.Neurosci. Lett.75: 49–54.
45.
45. Kovacs K, Kiss JZ, and Makara G (1986). Glucocorticoid implants around the hypothalamic paraventricular nucleus prevent the increase of corticotropin-releasing factor and arginine vasopressin immunostaining induced by adrenalectomy.Neuroendocrinology44: 229–234.
46.
46. Krulich L, Koenig JI, Conway S, McCann SM, and Mayfield MA (1986). Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: Comparison with morphine.Neuroendocrinology42: 75–81.
47.
47. Krulich L, Koenig JI, Conway S, McCann SM, and Mayfield MA (1986). Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. II. GH and PRL release-inhibiting effects of the opioid kappa receptor agonists bremazocine and U-50,488.Neuroendocrinology42: 82–87.
48.
48. Lind RW, Swanson LW, and Sawchenko PE (1985). Anatomical evidence that neural circuits related to the subfornical organ contain angiotensin II.Brain Res. Bull.15: 79–82.
49.
49. Lind RW, Swanson LW, Bruhn TO, and Ganten D (1987). The distribution of angiotensin II-immuno-reactive cell and fibers in the paraventriculo-hypophysial system of the rat.Brain Res.388: 81–89.
50.
50. Lord JAH, Waterfield AA, Hughes J, and Kosterlitz HW (1977). Endogenous opioid peptides: Multiple agonists and receptors.Nature (London)267: 495–499.
51.
51. Martin JB and Reichlin S (1987). Cinical Neuroendocrinology.FA Davis Co., Philadelphia, PA.
52.
52. Martin WR, Eades CG, Thompson JA, Huppler RE, and Gilbert PE (1976). The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog.J. Pharmacol. Exp. Ther.197: 517–532.
53.
53. McCann SM (1957). The ACTH-releasing activity of extracts of the posterior lobe of the pituitaryin vivo. Endocrinology60: 664–676.
54.
54. McCann SM, Vijayan E, Koenig JI, and Krulich L (1982). The effects of neurotensin on anterior pituitary hormone secretion.Ann. NY Acad. Sci.400: 160–171.
55.
55. McDonald JK, Koenig JI, Gibbs DM, Collins P, and Noe BD (1987). High concentrations of neuropeptide Y in pituitary portal blood of rats.Neuroendocrinology46: 538–541.
56.
56. Meister B, Hokfelt T, Geffard M, and Oertel W (1988). Glutamic acid decarboxylase- and gamma-aminobutyric acid-like immunoreactivities in corticotropin-releasing factor-containing parvocellular neurons of the hypothalamic paraventricular nucleus.Neuroendocrinology48: 516–526.
57.
57. Mezey E, Kiss JZ, Mueller GP, Eskay R, O'Donohue TL, and Palkovits M (1985). Distribution of the pro-opiomelanocortin derived peptides, adrenocorticotrope hormone, alpha-melanocyte-stimulating hormone and beta-endorphin (ACTH, a-MSH, beta-END) in the rat hypothalamus.Brain Res.328: 341–347.
58.
58. Moore KE and Demarest KT (1982). Tuberoinfundibular and tuberohypophyseal dopaminergic neurons. In: Frontiers in Neuroendocrinology, WF Ganong and L Martini (eds). Raven Press, New York, 7: 161–190.
59.
59. Myers RD and McCaleb ML (1981). Peripheral and intrahypothalamic cholecystokinin act on the noradrenergic “feeding circuit” in the rat's diencephalon.Neuroscience6: 645–655.
60.
60. Nordstrom O, Melander T, Hokfelt T, Bartfai T, and Goldstein M (1987). Evidence for an inhibitory effect of the peptide galanin on dopamine release from the rat median eminence.Neurosci. Lett.73: 21–26.
61.
61. Pilotte NS and Porter JC (1981). Dopamine in hypophysial portal plasma and prolactin in systemic plasma of rats treated with 5-hydroxytryptamine.Endocrinology108: 2137–2141.
62.
62. Plotsky PM (1987). Regulation of hypophysiotropic factors mediating ACTH secretion.Ann. NY Acad. Sci.512: 205–217.
63.
63. Plotsky PM and Sawchenko PE (1987). Hypophysialportal plasma levels, median eminence content and immunohistochemical staining of corticotropin-releasing factor, arginine vasopressin and oxytocin following pharmacological adrenalectomy.Endocrinology120: 1361–1369.
65. Reichlin S (1988). Neuroendocrine significance of vasoactive intestinal polypeptide.Ann. NY Acad. Sci.527: 431–449.
66.
66. Risch SC, Janowsky DS, Judd LL, Gillin JC, and McClure SF (1983). The role of endogenous opioid systems in neuroendocrine regulation.Psychiatr. Clin. North Am.6: 429–441.
67.
67. Sapolsky R, Rivier C, Yamamoto G, Plotsky P, and Vale W (1987). Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor.Science238: 522–524.
68.
68. Sawchenko PE (1987). Adrenalectomy-induced enhancement of CRF- and vasopressin-immunoreactivity in parvocellular neurosecretory neurons: Anatomic, peptide and steroid specificity.J. Neurosci.7: 1093–1106.
69.
69. Sawchenko PE and Swanson LW (1982). The organization of noradrenergic pathways from the brainstem to the paraventricular and supraoptic nuclei in the rat.Brain Res. Rev.4: 275–325.
70.
70. Sawchenko PE, Swanson LW, Grzanna R, Howe PRC, Bloom SR, and Polak JM (1985). Colocalization of neuropeptide Y immunoreactivity in brainstem catecholaminergic neurons that project to the paraventricular and supraoptic nuclei in the rat.J. Comp. Neurol.241: 138–153.
71.
71. Sawchenko PE, Swanson LW, and Vale WW (1984). Co-expression of corticotropin-releasing factor and vasopressin immunoreactivity in parvocellular neurosecretory neurons of the adrenalectomized rat.Proc. Natl. Acad. Sci. USA81: 1883–1887.
72.
72. Schulz R, Wuster M, and Herz A.Pharmacological characterization of the epsilon-opioid receptor. J. Pharmacol. Exp. Ther.216: 604–606.
73.
73. Shimatsu A, Kato Y, Matsushita N, Katakami H, Yanaihara N, and Imura H (1982). Stimulation by serotonin of vasoactive intestinal polypeptide release into rat hypophysial portal blood.Endocrinology111: 338–340.
74.
74. Smith EM and Blalock JE (1981). Human lymphocyte production of ACTH and endorphin-like substances: Association with leukocyte interferon.Proc. Natl. Acad. Sci. USA78: 7530–7534.
75.
75. Smith EM, Meyer WJ, and Blalock JE (1982). Virus-induced increases in corticosterone in hypophysectomized mice: A possible lymphoid adrenal axis.Science218: 1311–1312.
76.
76. Spampinato S, Locatelli V, Cocchi D, Vincenti L, Bajusz S, Ferri S, and Muller EE (1979). Involvement of brain serotonin in the prolactin-releasing effect of opioid peptides.Endocrinology105: 163–170.
77.
77. Spiegel K, Kourides IA, and Pasternak GW (1982). Prolactin and growth hormone release by morphine in the rat: Different receptor mechanisms.Science217: 745–747.
78.
78. Swanson LW, Sawchenko PE, Lind RW, and Rho J-H (1987). The CRH motoneuron: Differential peptide regulation in neurons with possible synaptic, paracrine and endocrine outputs.Ann. NY Acad. Sci.512: 12–23.
79.
79. Swanson LW, Sawchenko PE, and Lind RW (1986). Regulation of multiple peptides in CRF parvocellular neurosecretory neurons: Implications for the stress response. In: Progress in Brain Research, T Hokfelt, K Fuxe, and B Pernow (eds). Elsevier, Amsterdam, 68: 169–190.
80.
80. Szafarczyk A, Alonso G, Ixart G, Malaval F, and Assenmacher I (1985). Diurnal-induced and stress-induced ACTH release is mediated by the ventral noradrenergic bundle. Am. J. Physiol.249: E219–E226.
81.
81. Szafarczyk A, Malaval F, Laurent A, Gibaud R, and Assenmacher I (1987). Further evidence for a central stimulatory role of catecholamines on adrenocorticotropin release in the rat.Endocrinology121: 883–892.
82.
82. Tatemoto K (1982). Neuropeptide Y: Complete amino acid sequence of the brain peptide.Proc. Natl. Acad. Sci. USA79: 5485–5489.
83.
83. Tatemoto K, Carlquist K, and Mutt V (1982). Neuropeptide Y–A novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide.Nature296: 659–661.
84.
84. Vale W, Speiss J, Rivier C, and Rivier J (1981). Characterization of a 41-residue ovine hypothalamic peptide that stimulates the secretion of corticotropin and beta-endorphin.Science213: 1394–1397.
85.
85. Valentino RJ and Wehby RG (1988). Corticotropin-releasing factor: Evidence for a neurotransmitter role in the locus ceruleus during hemodynamic stress.Neuroendocrinology48: 674–677.
86.
86. Wahlestedt C, Skagerberg G, Ekman R, Heilig M, Sundler F, and Hakanson R (1987). Neuropeptide Y (NPY) in the area of the hypothalamic paraventricular nucleus activates the pituitary-adrenocortical axis in the rat.Brain Res.417: 33–38.
87.
87. Weiner RI and Ganong WF (1978). Role of brain monoamines and histamine in regulation of anterior pituitary secretion.Physiol. Rev.58: 905–976.
88.
88. Wolfson B, Manning RW, Davis LG, Arentzen R, and Baldino F Jr (1985). Colocalization of corticotropin releasing factor and vasopressin mRNA in neurons after adrenalectomy.Nature315: 59–61.
89.
89. Wuster M, Schulz R, and Herz A (1978). Specificity of opioids towards the mu-, delta- and epsilon-opiate receptors.Neurosci. Lett.15: 193–198.
